Grants per year
Grants
- 16 Active
Search results
-
Active
Prot #NU 24N04: A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
Lorch, J.H.-M. (PD/PI)
5/30/25 → 5/30/28
Project: Research project
-
Prot #TP-CA-006: TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
Lorch, J.H.-M. (PD/PI)
11/14/24 → 11/14/27
Project: Research project
-
Prot #ALE.C04.01: A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cel
Lorch, J.H.-M. (PD/PI)
Ergomed Clinical Research Inc., Alentis Therapeutics AG
7/19/24 → 7/19/27
Project: Research project
-
Prot #XL092-305: A Phase 2/3, Randomized, Double-blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab vs Pembrolizumab in the First-line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous
Lorch, J.H.-M. (PD/PI)
Quintiles, Inc., Exelixis Inc.
5/22/24 → 5/22/27
Project: Research project
-
Prot #TAK-676-1002: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastat
Lorch, J.H.-M. (PD/PI)
Pharmaceutical Research Associates, Inc., Takeda Development Center Americas, Inc.
5/21/24 → 5/21/27
Project: Research project
-
Y24-28 Carryforward
Johnson, J. L. P. (Other), Karmali, R. (Other), Kirsammer, G. (Other) & Lorch, J.H.-M. (Other)
8/1/23 → 7/31/25
Project: Research project
-
Prot #XmAb808‐01: A Phase 1, First‐in‐Human, Dose‐Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
Lorch, J.H.-M. (PD/PI)
ICON Clinical Research, LLC, Xencor, Inc.
7/20/23 → 7/20/26
Project: Research project
-
Prot #19‐12021154: A Multicenter Phase 1 Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer
Lorch, J.H.-M. (PD/PI)
5/16/23 → 5/16/26
Project: Research project
-
Prot #SGNTV‐001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Lorch, J.H.-M. (PD/PI)
4/21/23 → 4/21/26
Project: Research project
-
Prot #CDRB436J12301: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV6
Lorch, J.H.-M. (PD/PI)
Novartis Pharmaceuticals Corporation
12/20/22 → 12/10/28
Project: Research project
-
Prot #XmAb23104-01: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb(R)23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Lorch, J.H.-M. (PD/PI)
ICON Clinical Research, LLC, Xencor, Inc.
10/26/22 → 10/26/25
Project: Research project
-
Prot #AN2025H0301: The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Boumber, Y. (PD/PI) & Lorch, J.H.-M. (PD/PI)
INC Research, LLC, Adlai Nortye USA Inc.
8/11/21 → 8/11/27
Project: Research project
-
Prot #BTCRC-HN17-111: Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-Positive Salivary Gland Carcinoma
Boumber, Y. (PD/PI) & Lorch, J.H.-M. (PD/PI)
Hoosier Cancer Research Network, Inc., Merck Sharp & Dohme Corporation
10/9/19 → 4/2/27
Project: Research project